Zim Laboratories has incorporated a wholly owned subsidiary in Chile to expand its pharmaceutical operations in the Latin American region. The entity, named ZIM Laboratories SpA, was registered in Santiago on September 9, 2026.

The company disclosed the incorporation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This follows an earlier intimation issued on February 11, 2026, regarding the planned setup.

Subsidiary Details

ZIM Laboratories Limited holds 100% ownership of the new entity. The parent company subscribed to 14,100 shares of the subsidiary at a face value of CLP 1,000 each. The total consideration was paid in cash.

Strategic Objective

The primary objective of establishing the subsidiary is the expansion and development of the pharmaceutical business in the LATAM region. No governmental or regulatory approvals are required for this acquisition structure.

The disclosure was signed by Piyush Siddhwar Nikhade, Company Secretary and Compliance Officer of Zim Laboratories Limited.

Zim Laboratories Limited shareholders have approved special resolutions to revise the remuneration structures for its top executives, including Managing Director Dr. Anwar Daud and Whole-Time Director Mr. Zulfiqar Kamal. The company disclosed the outcome of its postal ballot on August 12, 2026, confirming that both resolutions were passed with requisite majority following the conclusion of remote e-voting on August 11, 2026.

The voting process, conducted via the National Securities Depository Limited (NSDL) platform, saw significant participation from the promoter group. Dr. Daud and Mr. Kamal are directly interested in the respective resolutions, as confirmed in the explanatory statement.

Voting Results Breakdown

The scrutinizer’s report, submitted by Company Secretary Roshni Jethani, detailed the voting patterns across different shareholder categories for both resolutions. The results indicate near-unanimous support from the promoter group and strong backing from public institutional investors.

Note: Data reflects Resolution 1 (Dr. Anwar Daud). Resolution 2 (Mr. Zulfiqar Kamal) showed identical voting patterns with negligible variance in against votes.

What the Numbers Show

The voting data reveals a distinct divergence in engagement levels between shareholder categories. While the promoter group participated at a 100% rate, public non-institutional shareholders—who hold the largest share base of 36,531,220 shares—participated at only 24.58%. Despite this lower participation rate, the absolute number of votes cast by non-institutional public shareholders (8,977,739) accounted for approximately 34.7% of the total votes polled, underscoring their material influence on corporate governance outcomes despite lower individual engagement rates compared to promoters.

Procedural Details

The record date for determining eligibility to vote was July 3, 2026. As on that date, the company had 14,669 shareholders. The e-voting window remained open from July 13, 2026, at 9:00 am until August 11, 2026, at 5:00 pm. No invalid votes were recorded during the process. The scrutinizer’s report was countersigned by Chairman and Managing Director Anwar S. Daud.